STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

AI justification

[Auto-resolved by learned corrector: learned-map — A=MINT/B=MINT -> MINT (human chose this in 87% of 272 past reviews)] FDA rejection delays patient access and may reduce market competition, outweighing safety benefits. | The FDA's decision reflects a commitment to patient safety and regulatory rigor, aligning with SDG 3 and UDHR Article 25. However, the rejection also delays access to a potential treatment and may hinder market competition, creating a tension between immediate safety and long-t